The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Open accessAbstract
BACKGROUND: Coronavirus disease 2019 (Covid-19) pneumonia is often associated with hyperinflammation. Despite the disproportionate incidence of Covid-19 among underserved and racial and ethnic minority populations, the safety and efficacy of the anti-interleukin-6 receptor antibody tocilizumab in patients from these populations who are hospitalized with Covid-19 pneumonia are unclear. METHODS: We randomly assigned (in a 2:1 ratio) patients hospitalized with Covid-19 pneumonia who were not receiving mechanical ventilation to receive standard care plus one or two doses of either tocilizumab (8 mg per kilogram of body weight intravenously) or placebo. Site selection was focused on the inclusion of sites enrolling high-risk and minority populations. The primary outcome was mechanical ventilation or death by day 28. RESULTS: A total of 389 patients underwent randomization, and the modified intention-to-treat population included 249 patients in the tocilizumab group and 128 patients in the placebo group; 56.0% were Hispanic or Latino, 14.9% were Black, 12.7% were American Indian or Alaska Native, 12.7% were non-Hispanic White, and 3.7% were of other or unknown race or ethnic group. The cumulative percentage of patients who had received mechanical ventilation or who had died by day 28 was 12.0% (95% confidence interval [CI], 8.5 to 16.9) in the tocilizumab group and 19.3% (95% CI, 13.3 to 27.4) in the placebo group (hazard ratio for mechanical ventilation or death, 0.56; 95% CI, 0.33 to 0.97; P = 0.04 by the log-rank test). Clinical failure as assessed in a time-to-event analysis favored tocilizumab over placebo (hazard ratio, 0.55; 95% CI, 0.33 to 0.93). Death from any cause by day 28 occurred in 10.4% of the patients in the tocilizumab group and 8.6% of those in the placebo group (weighted difference, 2.0 percentage points; 95% CI, -5.2 to 7.8). In the safety population, serious adverse events occurred in 38 of 250 patients (15.2%) in the tocilizumab group and 25 of 127 patients (19.7%) in the placebo group. CONCLUSIONS: In hospitalized patients with Covid-19 pneumonia who were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death, but it did not improve survival. No new safety signals were identified. (Funded by Genentech; EMPACTA ClinicalTrials.gov number, NCT04372186.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Factors associated with COVID-19-related death using OpenSAFELY
Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2521-4 · Cited by 6,674
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045
Hospitalization and mortality among Black patients and White patients with Covid-19.
Price-Haywood, E. G., Burton, J., Fort, D., & Seoane, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmsa2011686 · Cited by 1,660
Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020.
Stokes, E. K., Zambrano, L. D., Anderson, K. N., Marder, E. P., Raz, K. M., El Burai Felix, S., Tie, Y., & Fullerton, K. E. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6924e2 · Cited by 1,538
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362
Self-citationThe Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance
Phelan, A. L., Katz, R., & Gostin, L. O. (2020) · JAMA · doi:10.1001/jama.2020.1097 · Cited by 1,207
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., Klein, M., & Weinberger, T. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.008 · Cited by 1,161
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
Rosas, I. O., Bräu, N., Waters, M., Go, R. C., Hunter, B. D., Bhagani, S., Skiest, D., Aziz, M. S., Cooper, N., Douglas, I. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028700 · Cited by 1,125
Factors associated with death in critically ill patients with coronavirus disease 2019 in the US
Gupta, S., Hayek, S. S., Wang, W., Chan, L., Mathews, K. S., Melamed, M. L., Brenner, S. K., Leonberg-Yoo, A., Schenck, E. J., Radbel, J., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.3596 · Cited by 957
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30173-9 · Cited by 939
Karagiannidis, C., Mostert, C., Hentschker, C., Voshaar, T., Malzahn, J., Schillinger, G., Klauber, J., Janssens, U., Marx, G., Weber-Carstens, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30316-7 · Cited by 785
Hermine, O., Mariette, X., Tharaux, P.-L., Resche-Rigon, M., Porcher, R., Ravaud, P., CORIMUNO-19 Collaborative Group, Bureau, S., Dougados, M., Tibi, A., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6820 · Cited by 734
Racial health disparities and covid-19 - caution and context
Chowkwanyun, M., & Reed, A. L. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2012910 · Cited by 706
The Toughest Triage — Allocating Ventilators in a Pandemic
Truog, R. D., Mitchell, C., & Daley, G. Q. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005689 · Cited by 700
Salvarani, C., Dolci, G., Massari, M., Merlo, D. F., Cavuto, S., Savoldi, L., Bruzzi, P., Boni, F., Braglia, L., Turrà, C., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6615 · Cited by 684
Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis
Aziz, M., Fatima, R., & Assaly, R. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25948 · Cited by 554
Structural Racism, Social Risk Factors, and Covid-19 — A Dangerous Convergence for Black Americans
Egede, L. E., & Walker, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2023616 · Cited by 553
Gupta, S., Wang, W., Hayek, S. S., Chan, L., Mathews, K. S., Melamed, M. L., Brenner, S. K., Leonberg-Yoo, A., Schenck, E. J., Radbel, J., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6252 · Cited by 535
The impact of ethnicity on clinical outcomes in COVID-19: A systematic review
Pan, D., Sze, S., Minhas, J. S., Bangash, M. N., Pareek, N., Divall, P., Williams, C. M., Oggioni, M. R., Squire, I. B., Nellums, L. B., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100404 · Cited by 519
ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019*
Auld, S. C., Caridi-Scheible, M., Blum, J. M., Robichaux, C., Kraft, C., Jacob, J. T., Jabaley, C. S., Carpenter, D., Kaplow, R., Hernandez-Romieu, A. C., et al. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004457 · Cited by 510
Fan, E., Beitler, J. R., Brochard, L., Calfee, C. S., Ferguson, N. D., Slutsky, A. S., & Brodie, D. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30304-0 · Cited by 473
Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey
Tzotzos, S. J., Fischer, B., Fischer, H., & Zeitlinger, M. (2020) · Critical Care · doi:10.1186/s13054-020-03240-7 · Cited by 463
The association of race and COVID-19 mortality
Golestaneh, L., Neugarten, J., Fisher, M., Billett, H. H., Gil, M. R., Johns, T., Yunes, M., Mokrzycki, M. H., Coco, M., Norris, K. C., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100455 · Cited by 240
Price, C. C., Altice, F. L., Shyr, Y., Koff, A., Pischel, L., Goshua, G., Azar, M. M., Mcmanus, D., Chen, S.-C., Gleeson, S. E., et al. (2020) · Chest · doi:10.1016/j.chest.2020.06.006 · Cited by 204
Racial Disproportionality in Covid Clinical Trials
Chastain, D. B., Osae, S. P., Henao-Martínez, A. F., Franco-Paredes, C., Chastain, J. S., & Young, H. N. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2021971 · Cited by 199
Africa in the Path of Covid-19
El-Sadr, W. M., & Justman, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2008193 · Cited by 197
Assessment of COVID-19 Hospitalizations by Race/Ethnicity in 12 States
Karaca-Mandic, P., Georgiou, A., & Sen, S. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.3857 · Cited by 194
Elevated interleukin‐6 is associated with severity of COVID‐19: A meta‐analysis
Zhu, J., Pang, J., Ji, P., Zhong, Z., Li, H., Li, B., & Zhang, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26085 · Cited by 132
Covid’s Color Line — Infectious Disease, Inequity, and Racial Justice
Evans, M. K. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2019445 · Cited by 115
Morrison, A. R., Johnson, J. M., Griebe, K. M., Jones, M. C., Stine, J. J., Hencken, L. N., To, L., Bianchini, M. L., Vahia, A. T., Swiderek, J. L., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102512 · Cited by 70
Mastroianni, A., Greco, S., Apuzzo, G., Santis, S. D., Oriolo, C., Zanolini, A., Chidichimo, L., & Vangeli, V. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100410 · Cited by 33
Cited by
Interleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00676-0 · Cited by 1,983
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Morris, E. C., Neelapu, S. S., Giavridis, T., & Sadelain, M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00547-6 · Cited by 1,104
RECOVERY Collaborative Group (2021) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · doi:10.17863/cam.70428 · Cited by 1,067
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
The REMAP-CAP, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103417 · Cited by 941
Metadata
- Authors
- Salama, C., Han, J., Yau, L., Reiss, W. G., Kramer, B., Neidhart, J. D., Criner, G. J., Kaplan-Lewis, E., Baden, R., Pandit, L., Cameron, M. L., Garcia-Diaz, J., Chávez, V., Mekebeb-Reuter, M., Lima de Menezes, F., Shah, R., González-Lara, M. F., Assman, B., Freedman, J., & Mohan, S. V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-07
- Volume
- 384
- Issue
- 1
- Pages
- 20-30
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3110844195
- Cited by
- 1,291
- References
- 38
- FWCI
- 33.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.